Sandra Calman is an accomplished physician and clinical development expert in both biotechnology and pharmaceutical industries. Graduating with a Diploma in General Studies as Valedictorian "A" from West High School in Salt Lake City, Calman completed her Honors BS degrees in Biology (Genetics) and Applied Nutrition (Biochemistry), Magna Cum Laude, at the University of Utah. Her academic pursuits culminated in a Doctor of Medicine degree, accredited by AAD and AAFP at the U of U Medical School.

Calman's illustrious career encompasses more than two decades of experience serving in various capacities and leadership roles. She began as an Associate Physician at Ogden Family Clinic before transitioning to become a Board Certified Physician in Family Practice at the University of Utah. She furthered her education and became a Board-Certified Physician by AAD at the McKay Dee Rural Tract – Family Practice Program at the University of Utah.

Calman has served as the CEO and Founding Partner at Global Safety Physician, Medical Monitor, and Clinical Development Consultant for Safety Physician Associates Corp. She has also held senior positions such as Safety Physician and Global Medical Monitor, Clinical Development Executive at SPA Corp, and Biotechnology and Pharmaceutical Clinical Trials Expert Witness at the Securities and Exchange Commission.

Calman has also worked in various executive and leadership positions, including the Chief Medical Officer and Vice President of Clinical Development, Drug Safety, and Medical Affairs at Isolagen and Vice President of Clinical Development, Medical Affairs, and Drug Safety at Dey Pharma LP. She served as the Director of Clinical Development and Drug Safety (Global Medical Monitor) at Scios, Director, and Acting Chief Medical Officer at Dow Pharmaceutical Sciences.

Besides her work, Calman has indulged in charity work, serving as a partner in the Edmonds Family Medicine Clinic at EFMC, LLC. She has ample experience in clinical trial and product development, medical affairs, and drug safety.

--